AbCellera Biologics Inc. ABCL
11.95 USD -0.51 (-4.09%)
At closeNov 12, 2026, 4:01 AM EST
11.90 -0.05 -0.42%
Pre-market · Nov 12, 4:01 AM ET
11.93 Day range 12.95
2.75 52-week range 15.02
- YTD
- +249.42%
- 1 year
- +198.00%
News
benzinga.com StoneX Maintains Buy on AbCellera Biologics, Raises Price Target to $15 StoneX analyst Robert Wasserman maintains AbCellera Biologics (NASDAQ:ABCL) with a Buy and raises the price target from $11 to $15.
benzinga.com Stifel Maintains Buy on AbCellera Biologics, Raises Price Target to $14 Stifel analyst Stephen Willey maintains AbCellera Biologics (NASDAQ:ABCL) with a Buy and raises the price target from $9 to $14.
seekingalpha.com AbCellera Biologics Inc. (ABCL) Q3 2026 Earnings Call Transcript AbCellera Biologics Inc. (ABCL) Q3 2026 Earnings Call Transcript
marketbeat.com What AbCellera Biologics (ABCL) Said on Its Q3 Earnings Call AbCellera Biologics NASDAQ: ABCL plans to advance its experimental hot flash treatment ABCL635 into late-stage development in 2027 after reporting positive mid-stage results, while shelving further…
zacks.com AbCellera Biologics Inc. (ABCL) Reports Q3 Loss, Tops Revenue Estimates AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.19 per share a year ago.
benzinga.com AbCellera Biologics Q3 2026 Earnings Call Transcript AbCellera Biologics (NASDAQ:ABCL) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…- benzinga.com AbCellera Biologics Q3 EPS $(0.13) Beats $(0.16) Estimate, Sales $10.639M Beat $8.416M Estimate AbCellera Biologics (NASDAQ:ABCL) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.16) by 18.75 percent. This is a 31.58 percent increase over losses of…
businesswire.com AbCellera Reports Q3 2026 Business Results VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Q3 2026 Business Results.
benzinga.com UBS Initiates Coverage On AbCellera Biologics with Buy Rating, Announces Price Target of $18 UBS analyst Alice Nettleton initiates coverage on AbCellera Biologics (NASDAQ:ABCL) with a Buy rating and announces Price Target of $18.